Assessment of Safety of GlaxoSmithKline Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus Vaccine, Infanrix-IPV When Administered According to the Approved Prescribing Information in Korea.

Trial Profile

Assessment of Safety of GlaxoSmithKline Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus Vaccine, Infanrix-IPV When Administered According to the Approved Prescribing Information in Korea.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2016

At a glance

  • Drugs DTaP poliovirus vaccine (Primary)
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Apr 2016 Status changed from recruiting to completed.
    • 21 Jul 2015 Planned number of patients changed from 600 to 456, as reported by ClinicalTrials.gov.
    • 21 Jul 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top